On December 31, 2021, the Company entered into a Supplementary Agreement with the Company’s Executive Vice President Zhigong Lin to appoint Lin as the Chief Executive Officer of GOF Biotechnologies, Inc.(“GOF”), a majority-owned subsidiary of the Company. Starting August 12, 2022, Zhigong Lin no longer holds position as AAGH’s Executive Vice President or Chief Executive Officer of GOF. Zhigong Lin’s new position is the advisor/ consultant of the Company. Lin no longer receives any monthly compensation.